Depression and Pain Perseverance Through Empowered Recovery Intervention
DAPPER
Pilot Study of Depression and Pain Perseverance Through Empowered Recovery (DAPPER) Intervention
3 other identifiers
interventional
34
1 country
1
Brief Summary
African American women who are 50 years of age and older with depressive symptoms, pain and difficulty with mobility will participate in the DAPPER intervention study that includes 8 nurse visits in participants' homes to help participants with participants' pain and mood.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable pain
Started Jan 2020
Longer than P75 for not_applicable pain
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 13, 2019
CompletedFirst Posted
Study publicly available on registry
September 16, 2019
CompletedStudy Start
First participant enrolled
January 2, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 30, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
November 30, 2023
CompletedResults Posted
Study results publicly available
June 29, 2025
CompletedNovember 19, 2025
November 1, 2025
3.9 years
September 13, 2019
April 14, 2025
November 7, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Pain Intensity as Assessed by the Patient Reported Outcomes Measurement Information System (PROMIS)
The PROMIS Intensity is used to measure pain intensity on a scale of 0-10. Higher scores indicate more pain intensity.
Baseline and 12 weeks
Depressive Symptoms as Assessed by the Patient Health Questionnaire 9 (PHQ-9)
The Patient Health Questionnaire 9 (PHQ-9) includes 9 questions related to the Diagnostic and Statistical Manual of Mental Disorders (DSM) diagnostic criteria for major depression. The PHQ-9 scores range from 0-27. Higher scores indicate more depressive symptoms.
Baseline and 12 weeks
Secondary Outcomes (4)
Interleukin (IL)-6 in Saliva (pg/ml)
Baseline and 12 weeks
Interleukin (IL)-8 in Saliva (pg/ml)
Pre intervention , Post intervention 12 weeks for Intervention arm
Interleukin (IL)-1 Beta in Saliva (pg/ml)
Baseline and Post intervention 12 weeks for intervention arm. Baseline for wait list control.
Tumor Necrosis Factor (TNF)-Alpha in Saliva (pg/ml)
Baseline and post intervention (12 weeks ) for intervention arm. Baseline only (wait list control arm)
Other Outcomes (9)
Physical Function as Assessed by the Katz Activities of Daily Living (ADL)
Baseline
Physical Function as Assessed by the Lawton's Instrumental Activities of Daily Living (IADL)
Baseline
Frailty as Assessed by the Frail Scale
Baseline
- +6 more other outcomes
Study Arms (2)
Intervention Arm
EXPERIMENTALThe intervention group will receive the intervention for 12 weeks. The wait list control group will have outcomes measured but will not receive the intervention at this time.
Wait List Control Arm
ACTIVE COMPARATOROnce the intervention group has completed the intervention the wait list control group will complete the intervention.
Interventions
The DAPPER program is person directed and will consist of 8 nurse visits during which the nurse assesses each participant for pain, depression and frailty and then implements a manualized individually tailored intervention. Participants will be randomized into either the intervention or the wait list control group. Once the intervention group has completed the intervention group's visits, the wait list control group will begin the waitlist control group's visits. All participants will all be offered the same information and format of nurse visits. The nurses will systematically tailor the content of the visits to the participants' risk profile and goals based on protocols. All participants will be assessed at the start of the study, at 12 weeks and 24 weeks.
Eligibility Criteria
You may qualify if:
- Self-report pain \>3 out of a 0 -10 scale that has lasted longer than 3 months and keeps subjects from doing at least one activity that subjects would like to do
- Self-Identify as African American/Black female
- Live in a community dwelling
- Score a 5 or higher on the PHQ-9 (depression measure) at least two times during a two week period (screening call and then at first data collection visit)
- Must be pre-frail (one or two criteria on frailty phenotype) or frail (three or more of the criteria on frailty phenotype)
- One ADL or IADL limitation
You may not qualify if:
- Hospitalized \> 3 times in the last year
- Participating in physical therapy
- Have a terminal diagnosis (\<1 year expected survival)
- \> moderate intellectual impairment (5-7 errors) based on the Short Portable Mental Status Questionnaire (SPMSQ)
- Unable to speak or understand English
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Johns Hopkins Universitylead
- Robert Wood Johnson Foundationcollaborator
- National Institute on Aging (NIA)collaborator
Study Sites (1)
Johns Hopkins School of Nursing
Baltimore, Maryland, 21205, United States
Related Publications (2)
Taylor JL, Clair CA, Lee JW, Atkins S, Riser TJ, Szanton SL, McCoy MC, Thorpe RJ Jr, Wang C, Gitlin LN. A protocol for a wait list control trial of an intervention to improve pain and depressive symptoms among middle-aged and older African American women. Contemp Clin Trials. 2023 Sep;132:107299. doi: 10.1016/j.cct.2023.107299. Epub 2023 Jul 20.
PMID: 37478967BACKGROUNDTaylor JL, Clair CA, Gitlin LN, Atkins S, Bandeen-Roche K, Abshire Saylor M, Hladek MD, Riser TJ, Thorpe RJ Jr, Szanton SL. Acceptability and Feasibility of a Pain and Depressive Symptoms Management Intervention in Middle-Aged and Older African American Women. Innov Aging. 2023 Sep 8;7(10):igad096. doi: 10.1093/geroni/igad096. eCollection 2023.
PMID: 38094930RESULT
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Results Point of Contact
- Title
- Janiece Taylor
- Organization
- Johns Hopkins School of Nursing
Study Officials
- PRINCIPAL INVESTIGATOR
Janiece L Taylor, PhD
Johns Hopkins School of Nursing
- STUDY DIRECTOR
Catherine Clair, MHS
Johns Hopkins University
Publication Agreements
- PI is Sponsor Employee
- No
- Restrictive Agreement
- No
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- INVESTIGATOR, OUTCOMES ASSESSOR
- Masking Details
- The statistician will be responsible for randomization and the investigator and study team will not have knowledge if participants are assigned to intervention group or wait list control group.
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 13, 2019
First Posted
September 16, 2019
Study Start
January 2, 2020
Primary Completion
November 30, 2023
Study Completion
November 30, 2023
Last Updated
November 19, 2025
Results First Posted
June 29, 2025
Record last verified: 2025-11
Data Sharing
- IPD Sharing
- Will not share